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Background: Faecal immunochemical test (FIT) is emerging as a valid test to rule- out 
the presence of colorectal cancer (CRC). However, the accuracy of FIT is dependent on 
the cut- off applied. An additional low- cost test could improve further detection of CRC.
Aims: To evaluate the efficacy of combined FIT and volatile organic compounds 
(VOC) in the detection of CRC within symptomatic populations.
Methods: Systematic reviews on the diagnostic accuracy of FIT and VOC, for the 
detection of CRC, were updated. Meta- analyses were performed adopting a bivari-
ate model for sensitivity and specificity. Clinical utility of combined FIT and VOC was 
estimated using Fagan's nomogram. Post- test probability of FIT negatives was used 
as a pre- test probability for VOC.
Results: The pooled sensitivity and specificity of FIT at 10 µg/g faeces, for the de-
tection of CRC, were 0.914 (95% confidence interval [CI] = 0.894- 0.936) and 0.783 
(CI = 0.850- 0.696), respectively. For VOC, the sensitivity was 0.837 (CI = 0.781- 
0.881) and the specificity was 0.803 (CI = 0.870- 0.712). The area under the curve 
for FIT and VOC were 0.926 and 0.885, respectively. In a population with 5% CRC 
prevalence, the estimated probability of having CRC following a negative FIT was 
0.5% and following both negative FIT and VOC was 0.1%.
Conclusions: In a FIT- negative symptomatic population, VOC can be a good test to 
rule- out the presence of CRC. The estimated probability reduction by 0.4% when 
both tests being negative offers adequate safety netting in primary care for the ex-
clusion of CRC. The number needed to colonoscope to identify one CRC is eight if 
either FIT or VOC positive. Cost- effectiveness and clinical accuracy of this approach 
will need further evaluation.
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1  | INTRODUC TION
Faecal immunochemical test (FIT) is presently used as a triage tool in 
the UK in symptomatic patients who are referred through the sus-
pected cancer pathway (National Institute of Care and Excellence 
NG12) criteria.1 The overall pooled sensitivity and specificity of FIT 
for the detection of CRC were 0.90 and 0.87, respectively.2 Although 
FIT is being used in the symptomatic population as a “rule- out” test 
for colorectal cancer (CRC) at lower thresholds, there is still a miss 
rate of 1 in 10. A study, which looked at symptomatic patients re-
ferred on a 2- week referral pathway, showed that the false- negative 
rate of FIT— at the cut- off of 10 µg/g faeces— was 14%.3 In screening 
populations, this could vary up to 66% depending on the cut- off val-
ues applied.4- 6 A false- negative FIT result can delay the diagnosis of 
CRC and could give false reassurance to patients. This will invari-
ably have serious consequences not only for patients but also on the 
healthcare systems.
Several studies have attempted to analyse factors affecting false- 
negative rates of FIT. A recent systematic review and meta- analysis 
had identified male sex, having a family history of CRC, history of 
smoking, high blood glucose levels and hypertension as being sig-
nificantly associated with high false- negative results.7 Interestingly, 
a study by Ibañez- Sanz et al5 concerning the diagnostic accuracy of 
FIT in a screening population showed that 94% of false- negative FIT 
values were below the limit of detection (below 4 µg/g faeces). This 
suggests that lowering the FIT cut- off below 10 µg/g faeces may not 
reduce false- negative rates significantly. Another quite recent study 
concluded that the sensitivity of FIT for stage I CRC was only 68% 
and, for stage III and IV cancers 82%- 89%.8 According to a recent 
systematic review and meta- analysis, sensitivity is even as low as 
40% for T1 colorectal cancers.9 In this context, introducing another 
test, as an adjunct to FIT, might help in improving the false- negative 
rates and reduce the number of cancers missed.
The detection of volatile organic compounds (VOC) emanating 
from bodily fluids has been shown to have a good diagnostic perfor-
mance for CRC.10- 13 A recent meta- analysis by Zhou et al14 showed 
that VOC had an overall sensitivity of 0.82 and specificity of 0.79 
for the detection of CRC. This suggests that VOC has potential to 
be used as a complementary test to FIT, in particular in, the FIT- 
negative group.
The aim of our article was to critically assess the clinical utility 
of VOC in the FIT- negative symptomatic population for the detec-
tion of CRC, utilising results from two meta- analyses. This study 
also evaluates different scenarios (lowering FIT threshold vs adding 
a second test) in order to combat FIT- negative CRC. This is a collab-
orative effort from major centres across EU and the UK— “VOC(F)IT 
working group.”
2  | METHODOLOGY
Systematic review and meta- analyses on (1) the diagnostic per-
formance of FIT for the detection of colorectal cancer in the 
symptomatic population and (2) the diagnostic performance of VOC 
for the detection of CRC were carried out as described below for 
the purpose of this study. Both of these reviews followed the guid-
ance laid out in the Cochrane handbook for diagnostic accuracy 
reviews.15 Clinical utility of VOC, in this study, is defined as the di-
agnostic effectiveness and usefulness of VOC in the FIT- negative 
population.16 The combination of tests refers to the analysis of VOC 
in the FIT- negative population in a sequential manner. All patients 
had a colonoscopy as a reference standard.
2.1 | Data sources and search strategy
2.1.1 | Systematic review and meta- analysis 1: the 
diagnostic performance of FIT for the detection of 
colorectal cancer in symptomatic population
The search strategy and the eligibility criteria were described in 
detail elsewhere.2 Literature search was re- performed using the 
same search strategy in Medline, EMBASE, Scopus, Cochrane 
and PubMed for articles published up to and including the 31st of 
December 2020, in order to update the systematic review. Only the 
articles which had looked at the FIT performance at the cut- off of 
10 µg/g faeces within a symptomatic population were considered for 
the purpose of this meta- analysis.
2.1.2 | Systematic review and meta- analysis 
2: the diagnostic performance of VOC for the 
detection of CRC
Literature search strategies were developed using medical subject 
headings (MeSH) and text words related to the title. The search 
was performed for articles published up to and including the 31st 
of December 2020, using Medline, Ovid, EMBASE, Scopus and 
Cochrane with various combinations of keywords and subject 
headings— “volatile organic compounds” and “colorectal neoplasm.” 
The following free words were also used in combination to ensure a 
maximum capture (“ion mobility spectrometry,” “gas chromatography 
mass spectrometry,” “Field Asymmetric Ion Mobility Spectrometry,” 
“selected ion flow tube mass spectrometry,” “electronic nose,” “vo-
lotolome,” “metobolome”). Reference lists of included manuscripts 
were also checked for additional studies. The detailed search strate-
gies for both meta- analyses are presented in the Supplementary File.
2.2 | Study selection
Studies were included based on the following inclusion criteria: 
(a) prospective and retrospective comparative cohort studies, case 
controlled studies, nested case- control studies, cross- sectional 
comparative studies and randomised controlled trials, (b) ex-
amined general adult human population of 18 years or older, (c) 
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published in English and were available as full texts, (d) CRC di-
agnosis that was made through colonoscopy, (e) studies that had 
reported adequate data to form 2 × 2 contingency table for true 
positives, false positives, false negatives and true negatives and (f) 
for VOC— studies which evaluated VOC in both symptomatic and 
screening population regardless of the sampling and the analysis 
method used; for FIT— studies that evaluated FIT performance in 
symptomatic population. The exclusion criteria were as follows: (a) 
studies which did not have a control group and (b) studies which 
were published as reviews or abstracts.
2.3 | Quality assessment
The Quadas- 2 tool was used to assess the risk of bias of the included 
studies. The studies were assessed under four domains— patient se-
lection, index test, reference standard and patient flow and timing; 
and then graded as “low risk,” “unclear” or “high risk.” Publication 
bias was assessed using funnel plots.
2.4 | Data synthesis and analysis
For both of the systematic reviews, the following data were extracted 
from the selected articles: authors, the year of publication, study 
years, the type of sample medium used, method used for the VOC 
analysis, number of patients with CRC, number of healthy controls, 
true positives (TP), true negatives (TN), false positives (FP) and false 
negatives (FN).
The R software was used for all of the statistical analysis.17 
If TP, TN, FP and FN were not reported explicitly, they were ex-
tracted from sensitivity and specificity and their corresponding 
confidence intervals or the cases used to compute them. Bivariate 
meta- analysis for sensitivity and specificity based on asymptotic 
joint distribution of sensitivity and specificity logits was performed 
using the package “mada” in R.18 As well as individual study sensi-
tivity and specificity and corresponding confidence intervals, for-
est plots used to summarise the resulted included 95% confidence 
intervals (CIs) from the bivariate meta- analysis. Confidence region 
for sensitivity and false- positive rate (1- specificity) and summary 
receiver operator curves (SROC) were also produced. A bivariate 
meta- regression analysis was performed to determine whether the 
VOC media and the analytical methods used contributed to the 
heterogeneity. Fagan's nomogram (a graphical tool for estimating 
how much the result on a diagnostic test changes the probability 
that a patient has a disease)19 was used to assess the clinical utility 
of FIT and VOC. The prevalence of CRC in a symptomatic popula-
tion was considered as a pre- test probability for the FIT nomogram 
and the post- test probability of CRC in a FIT- negative population 
was used as the pre- test probability for the VOC nomogram. Thus, 
F I G U R E  1   PRISMA flow diagram showing the study selection process for (A) faecal immunochemical test and (B) volatile organic 
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the post- test probability of CRC in both FIT- and VOC- negative 
population was estimated.
Number needed to scope per 1000 symptomatic patients was cal-
culated if VOC testing is performed in FIT negatives and a comparison 
was made with a scenario of lowering the FIT cut- off to 2 µg/g faeces.
3  | RESULTS
Overall, the search had identified 121 articles for FIT and 133 ar-
ticles for VOC. Among them, 15 studies20- 34 were included for FIT 
meta- analysis and 14 studies10- 13,35- 44 for VOC meta- analysis. The 
selection process of the studies, for both meta- analyses, are shown 
in the PRISMA diagram— Figure 1. The basic study characteristics are 
summarised in Tables 1 and 2.
The risk of bias assessment is summarised in Tables S1 and S2. 
The greatest risk of bias was identified in the flow and timing section 
for the studies included in FIT meta- analysis, where the duration be-
tween FIT and colonoscopy was not clearly reported. For the studies 
included in VOC meta- analysis, a lack of defined selection criteria 
and reliability of the index tests were the major contributory factors 
towards bias.
The funnel plots for publication bias are given in Figure S1. 
Deeks' regression test for funnel plot asymmetry showed an ab-
sence of publication bias among the studies included, in both FIT 
and VOC meta- analysis (P = 0.94 and P = 0.43, respectively).
TA B L E  1   Basic characteristics of the studies for FIT in symptomatic population and their true- positive, true- negative, false- positive and 














Chapman et al27 UK 2019 4 OC Sensor 35 530 333 1
Cubiella et al23 Spain 2014 20 OC Sensor 85 534 156 12
Digby et al28 UK 2020 10 HM- JACKarc 25 167 268 1
D'Souza et al (a)16 UK 2020 2 HM- JACKarc 319 6157 3336 10
D'Souza et al (b)16 UK 2020 10 HM- JACKarc 299 7930 1563 30
D'Souza et al (c)16 UK 2020 150 HM- JACKarc 233 8977 516 96
Godber et al24 UK 2016 10 HM- JACKarc 11 380 116 0
Hogberg et al14 Sweden 2017 50 Actin Faecal 
Blood
7 246 119 1
Mcsorley et al17 UK 2020 10 Many brands 252 2152 2423 14
Mowat et al15 UK 2016 10 OC Sensor 25 571 151 3
Navarro et al19 Spain 2020 10 FOB- GOLD 33 536 155 3
Nicholson et al18 UK 2020 10 HM- JACKarc 95 8943 848 10
Rodriguez- Alonso 
et al (a)25
Spain 2015 10 OC Sensor 29 777 196 1
Rodriguez- Alonso 
et al (b)25
Spain 2015 15 OC Sensor 29 809 164 1
Rodriguez- Alonso 
et al (c)25
Spain 2015 20 OC Sensor 28 838 135 2
Steel et al21 UK 2013 10 OC Sensor 6 257 17 0
Tehaar Sive Droste 
et al (a)26
Netherlands 2011 10 OC Sensor 102 1693 253 10
Tehaar Sive Droste 
et al (b)26
Netherlands 2011 15 OC Sensor 102 1727 219 10
Tehaar Sive Droste 
et al (c)26
Netherlands 2011 20 OC Sensor 101 1753 193 11
Tehaar Sive Droste 
et al (d)26
Netherlands 2011 30 OC Sensor 95 1788 158 17
Tehaar Sive Droste 
et al (e)26
Netherlands 2011 40 OC Sensor 94 1804 142 18
Tsapournas et al20 Sweden 2020 10 QuickRead go 12 177 52 1
Widlak et al22 UK 2017 7 HM- JACKarc 21 377 28 4
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3.1 | Bivariate analysis on the diagnostic accuracy of 
FIT and VOC in the detection of colorectal cancer
Eleven out of fifteen studies assessed the diagnostic accuracy of FIT 
at the cut- off of 10 µg/g faeces. Figure 2 represents the SROC curve 
analysis for FIT and VOC. The pooled sensitivity and specificity of 
FIT at the cut- off of 10 µg/g faeces, for the detection of CRC, were 
0.914 (CI = 0.894- 0.936) and 0.783 (CI = 0.850- 0.696), respectively. 
The sensitivity of VOC was 0.837 (CI = 0.781- 0.881) and specificity 
was 0.803 (CI = 0.870- 0.712). The area under the curve (AUC) for 
FIT was 0.926 and for VOC was 0.885. The positive and negative 
likelihood ratios for FIT were 4.19 and 0.11, respectively. For VOC, 
the positive likelihood ratio was 4.15 and the negative likelihood 
ratio was 0.21. The Forest plots for the sensitivity and specificity of 
F I G U R E  2   Summary receiver operator 
curve characteristics for volatile organic 
compounds and faecal immunochemical 
test. Red and green circles indicate 95% 
confidence intervals for VOC and FIT, 
respectively. The distribution of studies 
for VOC and FIT are represented by red 
and green dots. CRC, colorectal cancer; 
FIT, faecal immunochemical test; VOC, 
volatile organic compounds [Colour figure 
can be viewed at wileyonlinelibrary.com]
F I G U R E  3   Fagan's nomogram demonstrating the pre- test and post- test probabilities of (A) faecal immunochemical test and (B) volatile 
organic compounds. The post- test probability of CRC in FIT- negative group has been used as a pre- test probability for VOC. CRC, colorectal 
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FIT and VOC, in the detection of CRC, are shown in Figures S2 and 
S3, respectively.
The test of heterogeneity suggests the presence of significant 
heterogeneity among the studies included in VOC meta- analysis. 
The covariates included in the bivariate meta- regression analy-
sis were VOC sample media and the method of VOC analysis. The 
covariate sample media had three categories: breath, faeces and 
urine. The categories for analytical methods were gas chromatogra-
phy mass spectrometry (GC/MS), gas chromatography ion mobility 
spectrometry (GC/IMS), field asymmetric ion mobility spectrometry 
(FAIMS), selected ion flow tube mass spectrometry (SIFT/MS) and 
electronic nose (e- nose). This lead to the confirmation that the sam-
ple media and the analytical techniques contributed to heterogene-
ity. See Tables S3 and S4.
3.2 | Pre- test and post- test probabilities of CRC
The pooled positive likelihood ratio was 4.19 and the pooled neg-
ative likelihood ratio was 0.11. The prevalence of CRC in a symp-
tomatic population is considered as 5% (pre- test probability).2,45 
Figure 3 illustrates the Fagan's nomograms for pre- test and post- 
test probabilities of CRC, following positive and negative results of 
FIT and VOC. The probabilities of having CRC, following a positive 
and negative FIT, were 18.1% and 0.5%, respectively. When the FIT- 
negative group was further tested for VOC, the probability of having 
CRC following a negative VOC test (FIT negative and VOC negative) 
was 0.1%.
3.3 | Comparison of lowering the FIT cut- off to 
2 µg/g faeces vs VOC testing in FIT negatives per 
1000 symptomatic patients
Table 3 presents the different scenarios in order to minimise false- 
negative FIT rates. The sensitivity and specificity of FIT, at the cut- off 
of 2 µg/g faeces, were considered as 97% and 64%,22 respectively, 
for the calculations. At the FIT cut- off of 2 µg/g faeces, the number 
of cancers detected would be 48 per 1000 patients tested. The num-
ber of CRCs detected at the FIT cut- off of 10 µg/g faeces would be 
45 (five CRCs missed). However, four additional cancers would be 
detected, if the FIT- negative group is tested with VOC. The number 
needed to scope in both scenarios would be eight.
4  | DISCUSSION
Results of this study showed that the combination of FIT and VOC can 
be a better triage tool, for CRC in patients with lower gastrointestinal 
symptoms than FIT alone. Testing the FIT- negative group with VOC 
will reduce cancers missed. The combination of FIT and VOC has an 
overall estimated post- test probability of 0.1% for CRC in the sympto-
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The false- negative rates of the FIT could be minimised by either 
lowering the cut- off level or by carrying out a second test for the 
false- negative group. Reducing the cut- off, however, leads to high 
false- positive rates. D'souza et al22 demonstrated that FIT had a 
sensitivity of 97% and a specificity of 64%, at the cut- off of 2 µg/g 
faeces (lowest limit of detection [LoD]). Assuming the FIT cut- off is 
reduced to 2 µg/g faeces, within the symptomatic population, 39.8% 
will have tested positive and would have required a colonoscopy. 
This would certainly result in higher number of unnecessary colo-
noscopies as well as pressure on endoscopy services. Similarly, if FIT 
and VOC are to be used in a sequential testing manner, 40.6% will 
have needed colonoscopy having tested positive for FIT or VOC test.
It is important however to consider factors which could have in-
fluenced the outcome of the above assumptions. First, the lowest 
limit of quantitation (LoQ) for FIT is 7 µg/g faeces. Below this level, 
the margin of error is high and is not recommended by manufactur-
ers. Thus, precision estimates at a FIT threshold of 2 µg/g faeces 
are highly unreliable. Second, there was heterogeneity among the 
studies included in the meta- analysis for VOC. The heterogeneity 
was largely due to the sample media and the analytical methods 
used. Hence, the performance of VOC could be further improved, 
provided the sample media used and sample analysis techniques are 
optimised, and a universal standardised methodology is followed.46 
Third, certain studies included in the VOC meta- analysis had par-
ticipants from both screening and symptomatic population and 
data could not be retrieved for the symptomatic population alone. 
Additionally, this estimation is based on the evidence from two sep-
arate meta- analyses for FIT and VOC and formal studies assessing 
FIT and VOC in pair- wise manner are required.
Patients and health commissioners might have differing views 
with regard to the detection of CRC in FIT- negative group and its 
cost burden— though minimal as urine VOC cost (estimated), for 
example, £25/test (€28/test). Testing with VOC is still more cost- 
effective than a colonoscopy or missing a case of resectable CRC. 
An algorithm for symptomatic patients, using non- invasive tests in 
triaging referrals for colonoscopy, as depicted in Figure 4 could min-
imise the number of missed CRC cases.
CRC stages were not reported in all of the VOC studies; hence, 
diagnostic accuracy by disease staging could not be undertaken. 
Neidermaier et al8 recently demonstrated that the FIT levels vary 
according to the stage of CRC, even in those with FIT under 10 µg/g 
faeces. The currently accepted view is that VOC is produced as a 
result of fermentation of non- starchy polysaccharides mediated by 
a complex interaction between colonic cells and microbiota.47 This 
process is heavily influenced by external factors such as diet, smok-
ing and medication.48 Hence, it is reasonable to assume that the VOC 
profile would be different at different stages of CRC. Similarly, the 
effects of medications were not evaluated in the studies included for 
FIT meta- analysis.49 These could have influenced the outcome of this 
review. Larger diagnostic accuracy studies evaluating sample media 
and optimising analytical methods are required. One such study is 
already underway (ClinicalTrials.Gov trial number 04516785).
In summary, the combination of FIT and VOC in a sequential test-
ing manner (if negative) reduces the probability of having CRC from 
0.5% to 0.1%. The number needed to colonoscope in order to iden-
tity one cancer is eight. Given the non- invasive and relatively low- 
cost nature of VOCs, this would seem a reasonable option though 
would require formal evaluation.
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